	Discovery (Athens) cohort, N (%)	Validation (Yale) cohort, N (%)
Age (y)		
Median [Min, Max]	63.3 [34.6, 89.3]	60.1 [41.5, 82.3]
Sex		
Male	41 (82.0%)	26 (89.7%)
Female	9 (18.0%)	3 (10.3%)
Smoking (current/former)		
Yes	42 (84.0%)	21 (72.4%)
No	8 (16.0%)	8 (27.6%)
Alcohol (current/former)		
Yes	18 (36.0%)	12 (41.4%)
No	32 (64.0%)	17 (58.6%)
Primary Site		
Oral Cavity	23 (46.0%)	6 (20.7%)
Larynx	15 (30.0%)	6 (20.7%)
Oropharynx	9 (18.0%)	15 (51.7%)
Other	3 (6.0%	2 (6.9%)
Immunotherapy agent		
Nivolumab	45 (90.0%)	10 (34.5%)
Pembrolizumab	1 (2.0%)	19 (65.5%)
Other	4 (8.0%)	na
Immunotherapy line of treatment		
First	22 (44.0%)	21 (72.4%)
Second	28 (56.0%)	7 (24.1%)
Third	na	1 (3.4%)
Best overall response		
Complete response	3 (6.0%)	3 (10.3%)
Partial response	7 (14.0%)	7 (24.1%)
Stable disease	8 (16.0%)	5 (17.2%)
Progressive disease	32 (64.0%)	10 (34.5%)
Non evaluable	na	4 (13.8%)
Progression free survival (months)		
Mean (SD)	6.85 (9.25)	9.28 (10.8)
Overall survival (months)		
Mean (SD)	10.8 (11.2)	13.5 (11.4)

Supplemental Table 1. Clinical characteristics of the discovery (Athens, YTMA496) and validation (Yale, YTMA523) cohorts.